Target the Dusp1 in Jak2 dependent myeloproliferative neoplasm (MPN) for curative treatment

尽管酪氨酸激酶抑制剂（TKI）治疗在临床上作为抗癌药物的反应令人印象深刻， 治疗，它不是治愈性的。即使是最有效的激酶抑制剂对小的 对治疗不敏感的癌细胞群;表现为微小残留病变 （MRD）。同样地，用Jak 2抑制剂治疗的骨髓增生性疾病显示出内在的耐药性， TKI治疗。失败根除了持久的细胞，它们导致治疗后复发。治疗 对TKI的反应是由癌基因成瘾介导的;然而， 在癌基因成瘾的背景下，TKI诱导的细胞死亡尚不清楚。我们发现 MAPK磷酸酶，Dusp 1，是MPD中癌基因成瘾的关键介质，由以下突变驱动： JAK 2、MPL和CSF 3R。Dusp 1在MPD中的过表达消除了癌基因成瘾， TKI响应。Dusp 1的遗传和药理学抑制对Jak 2-V761 F具有合成致死性 和CSF 3 R-T618 I驱动的MPD。这项研究将解决小鼠模型的敏感性问题， MPD白血病起始细胞和原代患者标本单独破坏Dusp 1活性， 在TKI疗法的背景下。此外，我们建议开发特异性和有效的Dusp 1抑制剂， 利用结构功能研究进行临床应用。我们的成果应该加速发展 一种治疗MPD的方法。

Despite the impressive response to tyrosine kinase inhibitor (TKI) therapy in the clinic as an anti-cancer treatment, it is not curative. Even the most potent kinase inhibitors are ineffective against a small population of cancer cells, which are insensitive to treatment; manifesting as minimal residual disease (MRD). Likewise, myeloproliferative disorders treated with Jak2 inhibitors show intrinsic resistance to TKI treatment . Failure eradicate the persistent cells them leads to post-therapy relapse. Therapeutic response to TKI is mediated by oncogene-addiction; however, the molecular mechanisms governing TKI-induced cell death in the context of oncogene-addiction is not clearly understood. We find that MAPK phosphatase, Dusp1, is a critical mediator of oncogene-addiction in MPD driven by mutations in JAK2, MPL and CSF3R. Overexpression of Dusp1 in MPDs abrogates oncogene addiction and ablates TKI response. Both genetic and pharmacological inhibition of Dusp1 is synthetic lethal to Jak2-V761F and CSF3R-T618I driven MPDs. The proposed research will address the sensitivity of murine-model of MPD leukemia initiating cells and primary patient specimens to disrupting Dusp1 activity alone and in the context of TKI therapy. In addition, we propose to develop specific and potent Dusp1 inhibitor using structure function studies for clinical application. Our results should accelerate development of a curative therapy for MPDs.